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Background: Non-palpable breast cancers require localization-guided surgery and axillary staging using
sentinel lymph node biopsy (SLNB). This study investigated the novel technique of magnetic-guided
lesion localization and concurrent SLNB, which avoids the need for wire-guided localization and
radioisotopes.
Methods: An ultrasound-guided intratumoral injection of magnetic tracer (0⋅5ml) was performed in a
protocol-driven predefined minimum of ten patients with palpable breast cancer to assess the ability
of the magnetic tracer safely to localize the tumour at the site of injection and concurrently drain to the
lymphatics. Once successful lesion localization had been confirmed (peakmagnetometer count retained at
the centre of the tumour), the technique was undertaken in a further 20 patients with non-palpable breast
cancers awaiting wide local excision and SLNB. All patients underwent SLNB with both the magnetic and
standard dual (radioisotope and Patent Blue V dye) techniques.
Results: Thirty-two patients were recruited, of whom 12 (1 with bilateral disease) presented with
palpable and 20 with non-palpable breast cancer. Peak magnetometer counts were retained at the tumour
centre in all palpable (13) and non-palpable (20) breast cancers. Re-excisions for involved margins were
necessary in two patients with non-palpable breast cancers. The sentinel lymph node identification rates
were 28 of 33 procedures for themagnetic technique alone, 32 of 33 for themagnetic technique combined
with blue dye, and 32 of 33 for the standard dual technique.
Conclusion: Magnetic lesion localization is feasible, with intratumoral magnetic tracer injection com-
bined with a periareolar injection of blue dye for subsequent SNLB.
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Collaborators
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Introduction
One-third of all breast cancers are non-palpable at the
time of diagnosis1. The current standard treatment for
these clinically occult lesions is surgical excision by
wire-guided localization and axillary staging using sen-
tinel lymph node biopsy (SLNB). Despite being the
standard of care, wire-guided localization has significant
drawbacks, including technical difficulties, poor cosmetic
outcome, diathermy burns and high reoperation rates.
Consequently, alternative techniques have been developed
including radioguided localization and intraoperative
ultrasonography. These techniques have demonstrated
benefits over wire-guided localization in systematic
reviews and meta-analyses2,3. However, their uptake
has been limited owing to dependence on radioisotope
with its associated accessibility, legislative and handling
issues, and the difficulties in formal ultrasound training for
surgeons4. The technique of SLNB has also consequently
been vastly underused because of its dependence on
radioisotopes, with less than 60 per cent of eligible patients
in the developed world having access to the procedure5.
A novel magnetic technique was developed for SLNB6
and this formed the basis for the SentiMAG Multicentre
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Trial7, which demonstrated the non-inferiority of the
magnetic technique for SLNB detection in breast cancer
compared with the standard ‘dual technique’ comprising
use of radioisotope and blue dye. The findings of the Sen-
tiMAGMulticentre Trial7 were subsequently confirmed by
the Central-European SentiMAG Study8. Superparamag-
netic iron oxide (SPIO) has been used to perform SLNB
in breast cancer7–9, and is one of the most promising
radioisotope-free techniques10. Once injected interstitially
into the breast, the SPIO travels to the axillary lymph nodes
and is distributed within the sinuses, subcapsular space
and parenchyma of the nodes11. Iron is sequestered within
macrophages before being broken down and distributed
across iron stores in the body12. Themagnetic tracer can be
detected during surgery using a handheld magnetometer,
allowing the SLNB independent of radioisotopes7–9.
The localization properties of the magnetic tracer were
established in preclinical phantoms12, and an in vivo
porcine model was developed and used successfully to val-
idate the performance of magnetic SLNB and assessment
of localization properties13. The Magnetic Sentinel Node
and Occult Lesion Localization (MagSNOLL) Trial14
evaluated the feasibility of a magnetic dye-directed lesion
localization technique with concurrent SLNB, using the
magnetic technique. The protocol-driven analysis of the
first 20 patients with non-palpable breast cancers enrolled
is presented here.
Methods
The study was conducted at units experienced with the
use of the magnetic technique for SLNB in breast cancer.
The magnetic radiological localization procedure and the
surgical localization procedure with magnetic SLNB were
standard for all participating radiologists and surgeons.
Data collection was undertaken prospectively using HP
Teleform (Hewlett-Packard Autonomy, Cambridge, UK)
with either electronic clinical record forms or eForms.
Ethics committee approval was granted for this study
within the UK (13/LO/0636). The trial was registered
Fig. 1 Magnetic sentinel node and occult lesion localization
procedure. a Injection of 0⋅5ml of magnetic tracer (1) is followed
by placement of a non-ferromagnetic marker coil (2), solely for
the purpose of facilitating specimen intraoperative
radiography – not as part of the localization procedure.
b Intratumoral injection (0⋅5ml magnetic tracer) administered
under ultrasound guidance in the radiology suite.
c Ultrasound-guided skin marking over the site of the breast
cancer
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with the UK Clinical Research Network (ISRCTN
68689512, UKCRN 14979).
Patient recruitment
Between 4 August 2013 and 8 June 2014, patients with
histologically confirmed invasive breast cancer visible on
ultrasound imaging and suitable for SLNB (normal or
indeterminate/abnormal preoperative axillary ultrasono-
graphy and benign fine-needle aspiration or core biopsy)
were recruited, of whom a predefined minimum of ten of
the first recruited patients had to have a palpable breast
cancer. All patients had to be available for a minimum
of 12 months’ follow-up. Patients with intolerance or
hypersensitivity to iron or dextran compounds, who could
not or did not receive radioisotope for SLNB, suffered
from iron overload disease, and had pacemakers or other
implantable devices in the chest wall were excluded. In
practice, none of the patients met any of the exclusion
criteria. Potential patients were identified by investiga-
tors from multidisciplinary team meetings. An invitation
letter was sent to eligible patients together with a patient
information sheet. Patients who were willing to participate
in the study provided informed written consent on the day
of elective surgery or at a previous hospital visit. Details of
all patients approached about the trial were recorded on the
patient-screening log and kept in the investigator site files.
Magnetic sentinel node and occult lesion
localization
Within 24 h of surgery the patients received an intra-
tumoral injection of 0⋅5ml magnetic tracer (Sienna+®
(27mg iron per ml); Endomagnetics, Cambridge, UK) and
placement of a non-ferromagnetic marker coil under ultra-
sound guidance, followed by skin marking directly overly-
ing the lesion (Fig. 1). Patients received the standard pro-
tocol of the combined technique (radioisotope and Patent
Blue dye) for SLNB. SLNB was commenced, guided by a
handheld magnetometer (SentiMAG®; Endomagnetics);
the γ probe was used only after magnetometer-detected
nodes had been identified and removed for ex vivo counts.
The handheld magnetometer was used to localize the
centre of the tumour and confirm that the peak magne-
tometer count corresponded to the skin marking placed
by the radiologist. Surgical excision of the breast lesion
was undertaken. Once the surgeon was satisfied that
the lesion had been excised with satisfactory oncological
margin clearance, an intraoperative specimen radiograph
was taken to confirm that the marker coil was localized
satisfactorily within the specimen with adequate marginal
clearance (Fig. 2). Magnetometer counts were repeated on
Fig. 2 Intraoperative specimen X-ray demonstrating a cancer
located in the centre of the excised specimen (arrows mark
radiological tumour extent). A marker coil is visible near the
tumour centre. Standard orientation clips are visible (2 at
superior margin and 3 towards the nipple)
the excised specimen. If the surgeon was satisfied with the
oncological clearance, the wound was closed; otherwise
further cavity excisions were made. The specimen was
marked in accordance with standard local protocols and all
specimens were sent for histopathological assessment.
Histopathology
All histopathological evaluation was carried out according
to local protocols. Inadequate excision of invasive cancer
or incidental in situ disease was defined by margins of less
2mm at the outset of the trial according to the standard
local protocols at the lead site (Guy’s Hospital). These local
protocols were changed to less than 1mm for invasive and
less than 2mm for in situ disease in March 2014, and this
was the same as used at the second site (Cardiff). Nodes
were reported as normal or containing macrometastases
(larger than 2mm), micrometastases (2mm or less but
larger than 0⋅2mm) and isolated tumour cells (0⋅2mm or
smaller). The size of the largest metastatic deposit was
recorded.
Predefined endpoints
The primary endpoint was defined as successful localiza-
tion of breast cancer within excised specimens (peak
magnetometer count within the excised specimen;
corroboration with the skin marking overlying the lesion
after excision in patients who underwent mastectomy).
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Secondary endpoints were excised specimen margin
status; volume of excised specimens; calculated resec-
tion ratio (CRR), defined as total resection volume
(TRV)/optimal resection volume (ORV)15, and sentinel
lymph node (SLN) identification with each technique.
Results
A total of 33 procedures were performed in 32 patients (1
patient had bilateral breast cancer). The first 13 procedures
were done in symptomatic patients with palpable breast
cancers, of whom three underwent mastectomy. The
subsequent 20 patients had clinically occult, non-palpable
breast cancers. Patient and tumour characteristics are
shown in Table 1.
Table 1 Patient and tumour characteristics
No. of tumours*
Mammographic screen-detected
Yes 13
No 20
Age (years)†
29–50 3
51–69 24
≥70 5
Type of surgery
Mastectomy 6
Breast-conserving surgery 27
Node status by largest metastasis
No metastasis 27
ITC 1
Micrometastasis 2
Macrometastasis 3
Lymphovascular invasion
Yes 2
No 31
Tumour grade
1 8
2 21
3 4
Tumour size
T1 23
T2 8
T3 2
Oestrogen receptor status
Positive 28
Negative 5
HER2 status
Positive 2
Negative 31
Tumour type
Invasive, no special type 19
Invasive, pure special type 11
Mixed–lobular and no special type 1
Mixed–other and no special type 2
*Unless indicated otherwise; †number of patients. ITC, isolated tumour
cells; HER2, human epidermal growth factor receptor 2.
Lesion localization
Radiological intratumoral injection of 0⋅5ml magnetic
tracer was performed successfully in all 32 patients.
Table 2 Intraoperative localization and surgical excision of breast
cancers
No. of patients 32
No. of cancers treated 33
Successful localization of tumour at surgical excision site† 33
Non-palpable cancers 20
Surgical margin status for invasive ± in situ disease
Clear 18
Close 0
Involved 2
Optimal resection volume (cm3)* 22⋅5(12⋅4)
Total resection volume (cm3)* 49⋅5(30⋅6)
Calculated resection ratio* 2⋅5(2⋅2)
*Values are mean(s.d.). †Retained peak magnetometer count at site of
original injection under ultrasound guidance.
Table 3 Identification (detection) rates and discordant
procedures by method of detection
Radioisotope+blue dye
Failed
detection
Successful
detection Total
Magnetic technique
Failed detection 0 5 5
Successful detection 1 27 28
Total 1 32 33
Magnetic technique+blue dye
Failed detection 0 1 1
Successful detection 1 31 32
Total 1 32 33
Discordance is six of 33 procedures for magnetic technique alone versus
standard dual technique, and two of 33 for magnetic technique+ blue dye
versus standard dual technique.
Table 4 Number of nodes removed in the study cohort (33
tumours) and mean per tumour, by mode of detection
Radioisotope+blue dye
Failed
detection
Successful
detection Total
Magnetic technique
Failed detection 0 (0) 15 (0⋅45) 15 (0⋅45)
Successful detection 5 (0⋅15) 47 (1⋅43) 52 (1⋅58)
Total 5 (0⋅15) 62 (1⋅88) 67 (2⋅03)
Magnetic technique+blue dye
Failed detection 0 (0) 7 (0⋅21) 7 (0⋅21)
Successful detection 5 (0⋅15) 55 (1⋅67) 60 (1⋅82)
Total 5 (0⋅15) 62 (1⋅88) 67 (2⋅03)
Values are number of tumours removed in the study cohort, with mean
per tumour in parentheses. Discordance is 20 (30 per cent) of 67 nodes
for magnetic technique alone versus standard dual technique, and 12 (18
per cent) of 67 for magnetic technique+ blue dye versus standard dual
technique.
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Fig. 3 Relationship between ex vivo magnetometer count of the
‘hottest’ node retrieved for each patient and time between
injection of the magnetic tracer and surgery
Successful intraoperative localization, corresponding to the
presence of peak magnetometer counts within the excised
specimens, was also achieved in all instances (Table 2).
Spillage of iron oxide at the skin puncture site on with-
drawal of the needle posed a technical challenge. This was
recognized and avoided by aspiration of the syringe before
removal of the needle from the tumour centre. Two of the
20 patients with non-palpable breast cancers required a sur-
gical re-excision (second operation) owing to the presence
of incidental in situ disease at the excised specimenmargins.
The mean(s.d.) CRR was 2⋅5(2⋅2) for the non-palpable
lesions (Table 2).
Sentinel lymph node biopsy
The SLNwas identified successfully in 28 of 33 procedures
(28 of 32 patients) by the magnetic technique alone, 32 of
33 procedures by the magnetic and blue dye techniques
combined, and 32 of 33 procedures with the standard dual
technique (Table 3). Discordance between the standard and
magnetic techniques was observed in six of 33 procedures
and 20 (30 per cent) of 67 nodes retrieved (Table 4). This
was reduced to two of 33 procedures, and 12 (18 per cent)
of 67 nodes respectively with the addition of blue dye to the
magnetic technique. The single failed SLNB procedure
using the standard technique and five using the magnetic
technique proved to be negative on final histology. Of
the 33 procedures performed, there were five instances
of nodal involvement, two owing to micrometastases
and three macrometastases. All macrometastases were
identified independently by both techniques, but one
micrometastasis was identified only using the magnetic
technique. Of the 67 nodes excised, 52 ‘true’ sentinel nodes
were identified by the magnetic technique alone, 60 by the
magnetic technique combined with blue dye, and 62 by the
standard dual technique (Table 4). The overall retrieval rate
was 2⋅03 nodes per procedure, 1⋅58 nodes for the magnetic
technique alone, 1⋅82 nodes for the magnetic technique
combined with blue dye, and 1⋅88 nodes for the standard
dual technique.
Fig. 3 shows that the ex vivo sentinel node count was
highest when tracer was injected the day before operation.
Discussion
The advent of screening programmes for breast cancer and
the development of advanced imaging modalities such as
MRI for diagnostic purposes has resulted in an increase in
the identification of non-palpable breast cancers. Despite
this increase in the burden of disease, current techniques
that allow localized surgical excision suffer from technical
difficulties, resulting in high re-excision rates3 as well as
logistical drawbacks; these prevent uptake2,3. It is therefore
imperative that new techniques are developed to overcome
current limitations.
The first feasibility study for a novel application of a
magnetic tracer for breast cancer localization and also
evaluating concurrent SLNB is presented here. This tech-
nique does not require use of a wire and radioisotopes. All
breast cancers were localized successfully in this series of
32 patients (33 procedures). It was predefined in the study
protocol that at least ten of the patients initially recruited
had to have palpable breast cancers that were visible on
ultrasound examination. This was necessary to confirm
the ability of the magnetic tracer to maintain a peak mag-
netometer count at the site of injection (within the centre
of the breast cancer), as demonstrated previously in vivo13.
All breast surgical localization procedures were carried
out at least 2 h after injection of the magnetic tracer. One
patient underwent SLNB before autologous breast recon-
struction and the subsequent breast surgical localization
was performed successfully 7 days after injection of the
magnetic tracer. For all tumours the peak magnetometer
counts were present at the original injection site, within
the centre of the palpable cancer.
Once it had been confirmed that safe localization of
tumour by magnetic tracer was feasible, progression was
made to the localization of non-palpable breast cancers.
The 20 patients with non-palpable breast cancers all
underwent successful surgical excision guided by peakmag-
netometer counts. Surgical re-excision (second operation)
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was required in two patients owing to margin involve-
ment with incidental in situ disease. These findings clearly
demonstrate the ability of this magnetic technique safely to
localize non-palpable lesions, allowing adequate excision.
The ORV and TRV volumes were computed, and applied
to create a CRR15. The mean(s.d.) CRR value was 2⋅5(2⋅2),
which compared favourably with results for wire-guided
localization, intraoperative ultrasonography and radio-
guided occult lesion localization, for which median values
of 2⋅8, 3⋅2 and 3⋅8 respectively have been recorded15. This
provides early support that the magnetic technique does
not result in excision of an excessive tissue volume.
SLNB is the standard procedure for axillary staging in
early breast cancer8,16–20. Intratumoral injection of the
magnetic tracer allowed localization and concurrent SLNB
to be performed successfully in 28 of 33 procedures. The
SLN identification rate was higher when the standard dual
technique with a periareolar subcutaneous injection was
used, with successful identification in 32 of 33 procedures.
There was discordance in SLN identification between the
magnetic and standard dual technique in six of 33 proce-
dures. The SLN identification rate in previous trials7,8 of
themagnetic technique performed only for SLNB in breast
cancer, with periareolar injections of magnetic tracer and
radioisotope, with or without blue dye, varied between 94
and 98 per cent with discordance rates of 2–6⋅8 per cent.
Therefore, in the present study the location of the injec-
tion of the magnetic tracer is most likely responsible for
the inferior SLN identification rate for the magnetic tech-
nique compared with the standard dual technique and the
observed high discordance rates.
When the magnetic tracer was combined with blue dye,
SLN identification was successful in 32 of 33 procedures
overall. This is consistent with studies21–24 that applied
a single intratumoral injection of radioisotope for sen-
tinel node and occult lesion localization, which reported
SLN identification rates between 79 and 91 per cent when
radioisotope alone was used, rising to 90–98 per cent with
the addition of periareolar injection of blue dye. Here, the
overall and mean number of sentinel nodes excised was
found to be similar with themagnetic technique (mean 1⋅58
nodes for magnetic technique alone; 1⋅82 nodes with addi-
tion of blue dye) compared with the dual technique (1⋅88
nodes). This is consistent with previous studies7–9 formag-
netic SLNB, which recorded retrieval of about two nodes
per procedure for the magnetic technique.
The magnetic tracer was shown to remain localized for
1week, after which peak magnetometer counts were still
present at the injection site at surgery, although this was
tested only in a single patient. Should the retention of
magnetic tracer at the site of injection be further confirmed
beyond this time frame, the technique could potentially
be applied as a marker after breast biopsy, or even before
primary chemotherapy, and could subsequently be used for
surgical excision without additional wire localization.
Concurrent SLNB performed after intratumoral injec-
tion of magnetic tracer demonstrated an inferior SLN
identification rate compared with the standard dual tech-
nique. However, when blue dye was also included with
the magnetic tracer the identification rates were similar
(success in 32 of 33 procedures). This suggests that, with
the present technique, intratumoral injection of magnetic
tracer on its own without blue dye would not provide
satisfactory SLN identification. The highest ex vivo sen-
tinel node counts were recorded in patients who underwent
injection of the magnetic tracer the day before surgery.
This suggests that lymphatic uptake of magnetic tracer
from the injection site to the sentinel node continues
with time. Therefore, the SLN identification rate may
be improved by administering the localized injection the
day before surgery or even earlier. Alternatively, magnetic
SLNB identification could be improved by administering
an additional periareolar injection of magnetic tracer in the
operating theatre, as in the SentiMAG Multicentre Trial7.
The MagSNOLL Trial has demonstrated that the mag-
netic technique is feasible for breast cancer localization and
concurrent SLNB. This technique overcomes the limita-
tions of wire-guided and radioguided surgery for lesion
localization. Further studies should evaluate localization
with lower volumes of tracer at least a day before surgery.
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